Woodline Partners’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-35,875
| Closed | -$366K | – | 994 |
|
|
2025
Q1 | $366K | Sell |
35,875
-351,826
| -91% | -$3.59M | ﹤0.01% | 847 |
|
|
2024
Q4 | $6.14M | Sell |
387,701
-375,847
| -49% | -$5.95M | 0.04% | 442 |
|
|
2024
Q3 | $44.3M | Sell |
763,548
-12,297
| -2% | -$714K | 0.37% | 76 |
|
|
2024
Q2 | $35.5M | Buy |
775,845
+14,145
| +2% | +$646K | 0.34% | 85 |
|
|
2024
Q1 | $50.4M | Buy |
761,700
+177,908
| +30% | +$11.8M | 0.46% | 57 |
|
|
2023
Q4 | $23.2M | Sell |
583,792
-134,631
| -19% | -$5.35M | 0.25% | 122 |
|
|
2023
Q3 | $22.9M | Buy |
718,423
+438,722
| +157% | +$14M | 0.27% | 110 |
|
|
2023
Q2 | $11.2M | Buy |
279,701
+81,562
| +41% | +$3.28M | 0.13% | 191 |
|
|
2023
Q1 | $8.46M | Buy |
198,139
+1,440
| +0.7% | +$61.5K | 0.12% | 216 |
|
|
2022
Q4 | $9.45M | Sell |
196,699
-145,794
| -43% | -$7M | 0.13% | 222 |
|
|
2022
Q3 | $12.9M | Buy |
+342,493
| New | +$12.9M | 0.18% | 163 |
|
|
2022
Q2 | – | Sell |
-257,200
| Closed | -$14M | – | 842 |
|
|
2022
Q1 | $14M | Buy |
257,200
+180,988
| +237% | +$9.84M | 0.23% | 132 |
|
|
2021
Q4 | $4.46M | Sell |
76,212
-111,623
| -59% | -$6.53M | 0.06% | 297 |
|
|
2021
Q3 | $7.43M | Buy |
+187,835
| New | +$7.43M | 0.12% | 202 |
|